Information Provided By: 
Fly News Breaks for March 4, 2019
PTLA
Mar 4, 2019 | 07:43 EDT
Oppenheimer analyst Jay Olson raised his price target for Portola Pharmaceuticals to $42 from $30 as the company's update highlights increased focus on the U.S. Andexxa launch, positive CHMP opinion for andexanet in Europe, feedback from end of Phase 2 meeting with FDA for cerdulatinib, and $125M debt financing agreement. The analyst views all of these items as positives for Portola Pharmaceuticals' shareholders and reiterates an Outperform on the stock.
News For PTLA From the Last 2 Days
There are no results for your query PTLA
